Two signals are better than one: harnessing dual pathways for obesity and liver disease

Instead of jamming on just one brake pedal in a car, you're learning to press two at once—achieving better control with less side effects.

This means next-generation obesity drugs might target the body's own signaling systems more elegantly, addressing both weight and fatty liver at the same time.